Printer Friendly

SOMANETICS ANNOUNCES THIRD-QUARTER RESULTS

 SOMANETICS ANNOUNCES THIRD-QUARTER RESULTS
 TROY, Mich., Oct. 13 /PRNewswire/ -- Somanetics Corporation


(NASDAQ-NMS: SMTS) reported net losses of $1,045,055 ($0.10 per common share) and $3,282,607 ($0.39 per common share) for the third fiscal quarter and the nine-month period ended Aug. 31, 1992. These results compare to net losses of $421,793 ($0.07 per common share) and $1,277,628 ($0.30 per common share) for the same periods of fiscal 1991, respectively.
 On July 6, 1992, Somanetics announced that its INVOS(R) 3100 Cerebral Oximeter and disposable SomaSensor(R) has been cleared by the Food and Drug Administration for marketing, promotion and commercial sales.
 "Since we received clearance, we have undertaken extensive preparations in our manufacturing and production facilities and have added to our global distribution network, in preparation for our first shipments of the Cerebral Oximeter for resale. This is an exciting time for the company as we proceed to introduce this product which has life- saving potential to the marketplace," said Gary D. Lewis, Somanetics' chairman, president and chief executive officer.
 The Cerebral Oximeter is a monitor intended for use in a hospital's operating room, intensive care unit, recovery room and emergency room. It uses In Vivo Optical Spectroscopy (INVOS) technology to measure non- invasively, directly and continuously oxygen saturation of the blood in portions of an adult's brain.
 During the second fiscal quarter, the company's common shares and Class B warrants began trading on the NASDAQ National Market System under the symbols SMTS and SMTSZ, respectively. The last day of exercise for the Class B warrants is Feb. 23, 1993.
 SOMANETICS CORPORATION
 (A development stage company)
 Selected Income Statement Data
 For the Fiscal Quarters and Nine-Month Periods
 Ended Aug. 31, 1992 and 1991
 (In thousands, except share and per-share data)
 3 Months Nine Months
 Ended August 31, Ended August 31,
 (Unaudited) (Unaudited)
 1992 1991 1992 1991
 Total revenues $ 0 $110 $50 $110
 Gross margin 0 35 2 35
 Net loss 1,045 422 3,283 1,278
 Net loss per share $ 0.10 $ 0.07 $ 0.39 $ 0.30
 Weighted average
 number of shares
 outstanding 10,302,764 6,124,250 8,375,407 4,312,425
 SLECTED BALANCE SHEET DATA
 August 31, 1992 and November 30, 1991
 (In thousands)
 August 31, November 30,
 1992 1991
 (Unaudited)
 Total current assets $11,332 $3,546
 Total assets 12,038 3,903
 Total current liabilities 370 854
 Long-term debt and redeemable
 convertible preferred shares 85 100
 Shareholders' equity 11,583 2,949
 -0- 10/13/92 R
 /CONTACT: Mary Ann Robb, director of Corporate Communications, Somanetics Corporation, 313-689-3996/
 (SMTS) CO: Somanetics Corporation ST: Michigan IN: MTC SU: ERN


PS -- DE015 -- 9485 10/13/92 16:19 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1992
Words:454
Previous Article:SNET PROPOSES NEW TELECOMMUNICATIONS INITIATIVES TO SUPPORT ECONOMIC DEVELOPMENT
Next Article:WEAN INCORPORATED ANNOUNCES PROJECT FOR ANSHAN IRON AND STEEL IN CHINA
Topics:


Related Articles
SOMANETICS CORPORATION ANNOUNCES FISCAL SECOND-QUARTER RESULTS
SOMANETICS ANNOUNCES THIRD-QUARTER RESULTS
SOMANETICS' SECOND QUARTER RESULTS INCLUDE FIRST REVENUES FROM COMMERCIAL SALES OF CEREBRAL OXIMETER
SOMANETICS ANNOUNCES THIRD-QUARTER RESULTS
Somanetics Announces Third Quarter Results
Somanetics Corporation Announces Year-End Results
Somanetics Announces First Quarter Results
Somanetics Year-to-Date Results Exceed All of 1997 Annual Sales
Somanetics Reports 100% Sales Increase
Somanetics (SMTS) Reports Third Quarter Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters